Loading…
for educational and safety purposes
Gepirone and Deramciclane both come up in the same conversations; they overlap on anxiety relief. Gepirone: Gepirone spent more than two decades in regulatory purgatory before it ever reached a pharmacy shelf, and its story is really about how brutal the FDA approval bar can be even for a drug that eventually worked. Deramciclane: Deramciclane came out of EGIS Pharmaceuticals in Hungary as a non-benzodiazepine anxiolytic working through 5-HT2A/2C receptors instead of GABA-A, and Orion Pharma partnered on it to run one of the largest clinical programs in Orion's 20-year research history.
Gepirone spent more than two decades in regulatory purgatory before it ever reached a pharmacy shelf, and its story is really about how brutal the FDA approval bar can be even for a drug that eventually worked. Fabre-Kramer Pharmaceuticals (with Organon as an early partner) submitted gepirone for depression in the late 1990s and got rejected in 1999, then again after resubmission in 2001, again in 2003 to 2004, and a fourth time in 2007, each rejection hinging on inconsistent trial results even as some studies showed real separation from placebo. The company kept the compound alive through a formal dispute appeal granted in 2016, and the FDA finally approved gepirone extended-release as Exxua for major depressive disorder in September 2023, an almost 25-year odyssey from first submission to market. It is less a lost drug than a drug that got found again, after nearly disappearing for good.
Deramciclane came out of EGIS Pharmaceuticals in Hungary as a non-benzodiazepine anxiolytic working through 5-HT2A/2C receptors instead of GABA-A, and Orion Pharma partnered on it to run one of the largest clinical programs in Orion's 20-year research history. Early dose-finding data in generalized anxiety disorder actually looked encouraging; the 60 mg/day arm cleared the psychic-anxiety subscale of the HAM-A against placebo. That promise collapsed when the larger Phase III studies read out; Orion announced in 2003 that deramciclane simply lacked sufficient efficacy in GAD, closing out a program that had consumed years of investment on a hopeful mechanistic bet.
neither entry records receptor-level affinities yet; the ledgers above and each full entry carry what's known.